COLUMBIA, Md., June 14, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that a new peer reviewed manuscript entitled "Open Surgical Implantation of a Viable Cryopreserved Placental Membrane after Decompression and Neurolysis of Common Peroneal Nerve: a Case Series" has been published in Journal of Orthopaedic Surgery and Research and is available online . The purpose of the published study was to report on the rehabilitative outcomes associated with common peroneal nerve (CPN) decompression and neurolysis revision when performed with open surgical implantation of a viable cryopreserved placental membrane (vCPM). Seven patients, who failed previous surgery, underwent secondary CPN decompression and neurolysis with open surgical implantation of vCPM. All patients achieved motor function improvement and resumed proper gait pattern with a return to activity levels of daily living demonstrated prior to injurious event. There were no infections or other adverse events reported related to the use of vCPM. At an average of 16-month follow-up, all patients showed no recurrence of symptoms. The use of vCPM wrap as an adjunct to surgical repairs of CPN injuries may contribute to the positive clinical outcomes. About Grafix Grafix is a cryopreserved placental membrane comprised of an extracellular matrix (ECM) rich in collagen, growth factors, and viable cells native to the tissue. Grafix is processed using Osiris' proprietary technology; it is flexible and conforming and designed for application directly to hard-to-treat acute and chronic wounds, including but not limited to diabetic foot ulcers, venous leg ulcers and thermal burns. About Osiris Therapeutics Osiris Therapeutics, Inc., based in Columbia, Maryland, is a world leader in researching, developing, and marketing regenerative medicine products that improve health and lives of patients and lower overall healthcare costs. Having developed the world's first approved stem cell drug, the Company continues to advance its research and development in biotechnology by focusing on innovation in regenerative medicine — including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in wound care, orthopedics, and sports medicine, including Grafix®, Stravix®, BIO 4® (available exclusively through Stryker), and Cartiform®. Osiris, Grafix, Stravix and Cartiform are registered trademarks of Osiris Therapeutics, Inc., and BIO 4 is a registered trademark of Howmedica Osteonics Corp. Osiris makes no claims concerning functional activities of Grafix or Stravix. Although well characterized in scientific literature and studies, preservation of tissue integrity including cells may not be indicative of clinical outcome. More information can be found on the Company's website, www.Osiris.com. (OSIR-G) Forward-Looking Statements This press release contains forward-looking statements. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as "anticipate," "believe," "continue," "ongoing," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project" or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Examples of forward-looking statements may include, without limitation, statements regarding the anticipated efficiencies and advantages of products or services and the likelihood of customer clinical adoption of new services. Although well characterized in scientific literature and studies, preservation of tissue integrity including cells may not be indicative of clinical outcome. Accordingly, you should not unduly rely on these forward-looking statements. We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this press release or to reflect the occurrence of unanticipated events.
For additional information, please contact:Diane SavoieOsiris Therapeutics, Inc.(443) 545-1834 OsirisPR@Osiris.com